Our Tests Clinical Science Resources About Us For Patients For Investors Contact Us ABOUT US A global leader in innovative genomic technology and diagnostic tests. Our StoryOur TeamNewsCareersFunding Requests Dedicated to pristine science in personalized medicine. Agendia is the only molecular diagnostics company focused solely on breast cancer. With our groundbreaking genomic testing, we generate reliable and meaningful clinical data about the unique biology of a woman’s breast cancer. Backed by prestigious physicians and institutions globally, we are shifting the standard of care towards more ideal, personalized treatment. MAMMAPRINT + BLUEPRINT > OUR MISSION Providing clarity and confidence on the path to recovery. We believe in the power of genomic testing to better inform the patient journey – from the moment of diagnosis to remission, and beyond. It sheds light on complex treatment decisions, leading to the most relevant and targeted approach for each individual patient. In helping doctors achieve the best possible outcomes, we hope to improve their patients’ overall quality of life. We do this for the people who have to watch their mother or daughter go through a debilitating disease. For the women who don’t need treatment, but do it anyway. — Mark R. Straley, CEO, Agendia FUTURE OUTLOOK Growth in translational research. Multiplying Data Sets By continuing to generate comprehensive clinical data, we are able to further develop our pipeline of products for the breast cancer market. Expanding Access Having already launched our CE-marked test suite in Europe, Latin America and Asia, we are reaching deeper into global markets, enabling wider access to our testing platforms. Building Networks We work with leading academic institutions, cancer centers and advocacy organizations to broaden our understanding of patient needs, genomics and cancer biology. Ongoing Studies Through key partnerships, we are advancing a number of clinical trials, including I-SPY2 and the FLEX Study, that will ultimately impact how breast cancer is treated. Awards and accolades. Named one of “America’s Fastest-Growing Private Companies” on 2020 INC 5000 The American Society of Breast Surgeon Foundation Award The American Medical Association Award Susan G. Komen The Brinker Award for Scientific Distinction AACR Outstanding Investigator Award for Breast Cancer Research Co-founder, Laura van ‘t Veer, inducted into the 2020 class of “Giants of Cancer Care” in Cancer Diagnostics Co-founder Laura van ‘t Veer, given the European Union Women Innovator Award Co-founder, René Bernards, elected as an international member of the National Academy of Sciences (NAS) OUR HISTORY Founded on a desire to predict which cancers would metastasize. Whereas previous science relied on clinical factors, we believed we could better tailor results to a patient’s tumor. Since inception in 2003, we have become a powerhouse in precision oncology with a growing global base of partners and patients. 1 2 3 4 Quick Links Our Tests Resources Landmark Trials Order A Test For Patients Legal Privacy Policy Legal & Compliance Terms & Conditions Licenses & Accreditations Contact For the US, Puerto Rico, Canada and South America Agendia Inc. USA, 22 Morgan, Irvine, CA 92618 (888) 321-2732 customercare@agendia.com For outside the Americas Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands +31 (0)20 462 1510 customerservice@agendia.com © 2021 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc. This website uses cookies to provide you with the best possible experience. By using this website, you agree to our terms and conditions and privacy policy. ACCEPT